---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-043017"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T01:44:55.559462+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Armata receives $4.65M additional DoD funding for phage therapy trial; topline data Q2 2025

## Summary
- Received $4.65M additional non-dilutive DoD funding for AP-SA02; total award now $26.2M.
- Phase 1b/2a diSArm trial of AP-SA02 for S. aureus bacteremia enrolled 50 subjects; last visit Jan 2025.
- Two subsets observed: one with in vivo phage amplification suggesting phage activity despite antibiotics.
- Topline data expected in Q2 2025 to inform optimal dose for larger efficacy trial.
- Going concern note in 2024 10-K remains unchanged per company disclosure.

## SEC filing metadata
- accession: 0001104659-25-043017
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465925043017/0001104659-25-043017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465925043017/tm2513778d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-043017
- JSON: https://secwatch.observer/filing/0001104659-25-043017.json
- Plain text: https://secwatch.observer/filing/0001104659-25-043017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.